Intraarterial beta irradiation to reduce restenosis after PTCA. Experimental and clinical experience.
The present data demonstrate clinical feasibility of intracoronary beta brachytherapy and fail to reveal any complications that could be attributed to it. Definitive conclusions regarding safety will have to await longer term evaluation. Proof of efficacy will require strict dose finding evaluation of higher doses than those used in the present pilot study followed by a controlled, randomized trial using both clinical and angiographic end-points.
Verin
V
V
Cardiology Center, University Hospital, Geneva, Switzerland. verin-vitali@diogenes-hcuge.ch
Popowski
Y
Y
D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000295:instrumentation*; D000818:Animals; D001610:Beta Particles; D001918:Brachytherapy / Q000295:instrumentation*; D003327:Coronary Disease / Q000473:pathology / Q000532:radiotherapy*; D003331:Coronary Vessels / Q000473:pathology; D004867:Equipment Design; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008297:Male; D010865:Pilot Projects; D011817:Rabbits; D012008:Recurrence; D019233:Retreatment